ASH 2023 | Loncastuximab tesirine plus rituximab in R/R follicular lymphoma
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, discusses a Phase II study (NCT04998669) into limited-duration loncastuximab tesirine (an antibody-drug conjugate) with rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL). This regimen was well tolerated and produced a high metabolic complete response (CR) rate in patients, including those who were considered high-risk. Dr Alderuccio hopes that a subsequent multi-center clinical trial will verify these findings in a larger cohort. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Genmab, ADC Therapeutics, BeiGene
Consultancy: Abbvie, ADC Therapeutics, Genentech, Regeneron
